PFM Health Sciences LP purchased a new stake in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 86,934 shares of the company’s stock, valued at approximately $2,226,000. PFM Health Sciences LP owned about 0.15% of ARK Genomic Revolution ETF as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the first quarter worth about $49,000. Cetera Investment Advisers increased its holdings in shares of ARK Genomic Revolution ETF by 290.7% during the 1st quarter. Cetera Investment Advisers now owns 140,897 shares of the company’s stock valued at $4,052,000 after purchasing an additional 104,831 shares in the last quarter. CWM LLC boosted its holdings in ARK Genomic Revolution ETF by 7.7% during the second quarter. CWM LLC now owns 48,260 shares of the company’s stock worth $1,133,000 after buying an additional 3,432 shares in the last quarter. SG Americas Securities LLC boosted its holdings in ARK Genomic Revolution ETF by 5.4% during the second quarter. SG Americas Securities LLC now owns 129,356 shares of the company’s stock worth $3,037,000 after buying an additional 6,675 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in ARK Genomic Revolution ETF by 10.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 44,424 shares of the company’s stock valued at $1,043,000 after buying an additional 4,305 shares during the period.
ARK Genomic Revolution ETF Stock Performance
ARKG stock opened at $25.95 on Friday. The stock’s 50-day moving average price is $24.60 and its 200-day moving average price is $25.12.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- Why Are These Companies Considered Blue Chips?
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Technology Stocks Explained: Here’s What to Know About Tech
- MarketBeat Week in Review – 11/25 – 11/29
- Using the MarketBeat Stock Split Calculator
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.